Skip to content

The Study of Effectiveness of Zingiber cassumunar Roxb.(Plai) Mixed Cannabis sativa L. Leaf Oil for Chronic Pain in Elderly.Randomized controlled trial

The Study of Effectiveness of Zingiber cassumunar Roxb.(Plai) Mixed Cannabis sativa L. Leaf Oil for Chronic Pain in Elderly.Randomized controlled trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20211116004
Enrollment
126
Registered
2021-11-16
Start date
2021-12-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic pain in the elderly Chronic pain Elderly Cannabis Zingiber cassumunar

Interventions

Zingiber cassumunar Roxb.(Plai) Mixed Cannabis sativa L. Leaf Oil.Extemporaneous preparation manufactured by Thai traditional medicine in Wanonniwat Hospital based on department of Thai Traditional An
Experimental Drug,Active Comparator Drug
Experimental group,Control group

Sponsors

The Graduate School, KasetsartUniversity
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Who agreed to participate in the study and written informed consent to participate in study. 2. Elderly 60 years of age and older. 3. Diagnosed with pain and pain intensity of 4 or higher as assessed with numeric rating scale (NRS) and onset for 3 months or more. 5. No medication to treat pain during the study. 6. Not receive NSAIDs in the 48 hours before and not to use them during the study. 7. Not receive cannabis drug in the 1 week before and not to use them during the study. 8. Not receive topical drug in the 48 hours before and not to use them during the study. 9. No other treatment for pain relief in the 24 hours before and not to receive other treatment except as received by the investigator. 10. No underlying disease couse of chronic pain such as cancer, rheumatoid arthritis, etc. 11. Not cannabis allergy, plai and coconut oil. 12. Not Diclofenac allergy or serious allergic reactions to NSAIDs. 13. No asthma disease. 14. No gastrointestinal (GI) bleeding. 15. No hepatic or renal insufficiency. 16. Not taking warfarin.

Exclusion criteria

Exclusion criteria: 1. Allergy to the products provided by the researcher. 2. Unable to track information. 3. The patient does not want to continue useing the medicine.

Design outcomes

Primary

MeasureTime frame
numeric rating scale (NRS) 0, 30 mins, 1 days, 3 days, 7 days and 14 days numeric rating scale (NRS)

Secondary

MeasureTime frame
N/A N/A N/A

Countries

Thailand

Contacts

Public ContactMathawee Luplipon

Wanonniwat Hospital

Mathawee.l@ku.th0934164756

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026